JAK inhibitors:
Baricitinib is a well-known anti-inflammatory drug and a potent inhibitor of AAK1 involved in endocytosis. The adverse outcome which is reported significantly is upper respiratory tract infection.[9]Although the therapeutic doses reduce inflammation, the infectivity of the virus is not reduced. Therefore, combination therapy can be proved beneficial due to less drug interaction. Combination therapy trials have been initiated. One open-label non-randomized trial uses this therapy to treat moderate and severe patients of COVID-19. Moreover, other trials treat patients with SARS CoV-2 pneumonia with this combination therapy41.